MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.68 (+101.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MACROGENICS INC grew revenue 11.7% to $167.67M over the twelve months to Jun 30, 2026. Free cash flow was -$65.54M.
Revenue
$167.67M
+11.7% vs. a year earlier
Operating income
-$40.75M
TTM Q2 2026
Free cash flow
-$65.54M
TTM Q2 2026
EPS, diluted
-$0.22
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $211.77M
- P/E ratio
- –
- Price to sales
- 1.26
- Price to book
- 4.94
- Dividend yield
- –
- Free cash flow yield
- -30.95%
Fundamentals
- Revenue
- $167.67M
- Net income
- -$14.59M
- EPS, diluted
- -$0.22
- Free cash flow
- -$65.54M
- Book value per share
- $0.67
- Diluted shares
- 64M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$167.67M+11.7% YoY
Gross profit
–
Operating income
-$40.75M
Net income
-$14.59M
EPS, diluted
-$0.22
Free cash flow
-$65.54M
Reported periodTrailing twelve months